文献速递瓣膜病与结构性心脏病

SOURCE 3注册研究:最新一代SAPIEN 3经导管心脏瓣膜欧洲上市后注册研究的设计与30天结果

SOURCE 3 Registry: Design and 30-Day Results of the European Postapproval Registry of the Latest Generation of the SAPIEN 3 Transcatheter Heart Valve.
PubMed 文献 · Circulation · 2017-01-19

SOURCE 3是一项欧洲多中心观察性注册研究,旨在记录SAPIEN 3经导管心脏瓣膜获欧洲批准后的临床安全性与性能。2014年7月至2015年10月共纳入来自10个国家80个中心的1950例患者,1947例接受经导管主动脉瓣植入术(TAVI)。30天全因死亡率为2.2%,心血管死亡率为1.1%,卒中为1.4%,主要血管并发症为4.1%,危及生命的出血为5%,TAVI后起搏器植入为12%,中度及以上瓣周反流为3.1%。结论认为该注册研究展示了欧洲日常实践中使用该第三代TAVI器械的当代趋势和良好结局。

要点

  • SOURCE 3注册研究纳入10国80中心1950例患者,1947例接受SAPIEN 3 TAVI,平均年龄81.6±6.6岁,女性占48.1%。
  • 30天全因死亡率为2.2%,心血管死亡率为1.1%,卒中为1.4%,主要血管并发症为4.1%,危及生命的出血为5%。
  • TAVI后起搏器植入率为12%,中度及以上瓣周反流在报告患者中占3.1%。

核心结论

  • SOURCE 3注册研究结果显示,在日常实践中使用该第三代TAVI器械时,展示了当代欧洲趋势和良好结局。

研究设计与样本

  • SOURCE 3注册研究是一项欧洲多中心观察性注册研究,旨在记录SAPIEN 3经导管心脏瓣膜获欧洲批准后的临床安全性与性能结局。
  • 2014年7月至2015年10月共纳入来自10个国家80个中心的1950例患者,其中1947例接受TAVI,平均年龄81.6±6.6岁,女性占48.1%。
  • 所有数据为自我报告,不良事件采用Valve Academic Research Consortium 2标准定义,并由独立临床事件委员会裁定。

主要发现

  • 主要合并症包括冠状动脉疾病(51.5%)、肾功能不全(27.4%)、糖尿病(29.5%)、慢性阻塞性肺疾病(16.0%),平均logistic EuroSCORE为18.3±13.2。
  • 经股动脉入路占87.1%(n=1695),非经股动脉入路252例;经股动脉手术中59.9%使用清醒镇静,50%的患者TAVI未行主动脉球囊瓣膜成形术。
  • 植入成功(1个瓣膜置入预期位置)率为98.3%,中转常规手术为0.6%,使用体外循环为0.7%。
  • 部位报告的30天全因死亡率为2.2%,心血管死亡率为1.1%,卒中为1.4%,主要血管并发症为4.1%,危及生命的出血为5%,TAVI后起搏器植入为12%。
  • 在报告患者中,中度及以上瓣周反流为3.1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The SOURCE 3 Registry (SAPIEN Aortic Bioprosthesis European Outcome) is a European multicenter, observational registry of the latest generation of transcatheter heart valve, the SAPIEN 3 (Edwards Lifesciences, Irvine, CA). Its purpose is to document outcomes of clinical safety and performance after European approval was given. METHODS: Here, we present the 30-day outcome of the SOURCE 3 Registry. All data are self-reported, and all participating centers have committed to support their consecutive experience with the SAPIEN 3 transcatheter heart valve, dependent on patient consent, before the start of the study. Adverse events are defined with Valve Academic Research Consortium 2 criteria and adjudicated by an independent clinical events committee. RESULTS: A total of 1950 patients from 80 centers in 10 countries were enrolled between July 2014 and October 2015. Of those, 1947 patients underwent transcatheter aortic valve implantation (TAVI) with the SAPIEN 3 (mean age, 81.6±6.6 years; 48.1% female). Main comorbidities included coronary artery disease (51.5%), renal insufficiency (27.4%), diabetes mellitus (29.5%), chronic obstructive pulmonary disease (16.0%), and a mean logistic EuroSCORE of 18.3±13.2. Transfemoral access was used in 87.1% (n=1695); nontransfemoral, in 252 patients. Conscious sedation was used in 59.9% of transfemoral procedures, and in 50% of patients, TAVI was performed without aortic balloon valvuloplasty. Implantation success (1 valve in the intended location) was 98.3%. Conversion to conventional surgery (0.6%) and use of cardiopulmonary bypass (0.7%) were rare. Adverse events were low, with site-reported 30-day all-cause mortality of 2.2%, cardiovascular mortality of 1.1%, stroke of 1.4%, major vascular complications of 4.1%, life-threatening bleeding of 5%, and post-TAVI pacemaker implantation of 12%. Moderate or greater paravalvular regurgitation was observed in 3.1% of reporting patients. CONCLUSIONS: Results from the SOURCE 3 Registry demonstrate contemporary European trends and good outcomes of TAVI in daily practice when this third-generation TAVI device is used.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Wendler O, Schymik G, Treede H, et al. SOURCE 3 Registry: Design and 30-Day Results of the European Postapproval Registry of the Latest Generation of the SAPIEN 3 Transcatheter Heart Valve. Circulation. 2017. PMID: 28104716. doi:10.1161/CIRCULATIONAHA.116.025103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。